One of the biggest ever FSGS clinical trial run by Travere called DUPLEX (close to 400 patients in a freaking Orphan indication) study was comparing Sparsentan to an ARB.
The first fully drug approved for IgAN is called TARPEYO, the trial design was 1) Trapeyo + RASi 2) Placebo + RASi
And now you are telling us all this nonsense about ARB and role DMX-200 can play in this FSGS space..
Come up with another lie now...This one is becoming too boring..
Ann: Notification of upcoming expiry of Unlisted Options, page-75
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.0¢ |
Change
0.055(9.91%) |
Mkt cap ! $335.3M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 61.5¢ | 56.5¢ | $1.938M | 3.305M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3652 | 60.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 27035 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |